Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe 10:56:29 2024-05-27 am EDT 5-day change 1st Jan Change
230 CHF -0.20% Intraday chart for Roche Holding AG -1.66% -5.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Roche renews diagnostic partnership with Hitachi CF
Roche appoints Director of Corporate Business Development CF
Roche and Hitachi High-Tech Extend Their 46-Year Partnership, Paving the Way for Further Breakthroughs in Diagnostic Testing CI
Roche Announces Management and Board Committee Changes CI
Swiss Market Index Slumps as Economic Data Triggers Rate Jitters Anew MT
ROCHE HOLDINGS AG : Gets a Neutral rating from Deutsche Bank ZD
UK Watchdog Launches Probe into Roche's LumiraDx Purchase MT
Roche, LumiraDx Deal Probed by U.K. Competition Watchdog DJ
Roche: FDA designation for blood test CF
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test MT
Roche Receives FDA Device Designation for Blood Test Measuring Lp(a) CI
Europe stock pickers go old-school to ride the next wave in AI RE
Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson... Our Logo
Roche: Breakthrough designation for inavolisib in breast cancer CF
Roche's Inavolisib Breast Cancer Treatment Gets FDA Breakthrough Therapy Designation DJ
Roche's Investigational Breast Cancer Treatment Granted Breakthrough Designation by US FDA MT
FDA Grants Breakthrough Therapy Designation to Roche's Inavolisib for Advanced Hormone Receptor-Positive, Hormone-Positive, Hormon Receptor 2-Negative Breast Cancer with A PIK3CA Mutation CI
UK Competition Watchdog Considers Probe into Roche's Purchase of LumiraDx Business MT
U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx DJ
UK'S CMA: INVITES COMMENTS ON ROCHE / LUMIRADX DEAL FROM ANY IN… RE
Health Care Up on Rotation to Sector From Rate-Sensitive Groups -- Health Care Roundup DJ
ROCHE HOLDINGS AG : UBS sticks Neutral ZD
Deutsche Bank Upgrades Roche to Hold from Sell MT
ROCHE : Deutsche Bank no longer sells CF
Roche: share price stands out, Deutsche Bank in support CF
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
230.4 CHF
Average target price
279.8 CHF
Spread / Average Target
+21.46%
Consensus
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. News Roche Holding AG
  5. Roche’s Multiple Sclerosis Injection Controls Relapses, Brain Lesions in Late-stage Trial